A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial

By sjmartinez • June 22, 2024

McKetin R, Degan TJ, Saunders L, Nguyen L, Dore G, Shoptaw S, Farrell M, Degenhardt L, Kelly PJ, Turner A, Clare PJ, Dean OM, Arunogiri S, Colledge-Frisby S, Koeijers J, Goodman-Meza D, Sinclair B, Reid D, Hill H, Hayllar J, Christmass M, Cordaro F, Lundin R, Liaw W, Liu D, Holyoak E, Wu BT, Keygan J, Kontogiannis A, Palmer L, Morrison C, Wrobel A, Hyland B, Byrne M, Russell S, Zahra E, Berk M. A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial. Trials. 2024 Jun 22;25(1):408. doi: 10.1186/s13063-024-08238-y. PMID: 38907288; PMCID: PMC11193254.

Tags: Addiction, Clinical Trial, depression, Infectious Diseases, Methamphetamine, Mirtazapine, pharmacotherapy, Psychiatry, Publications, sleep, substance use disorders, Treatment

Diagnostic Value of Inter-Eye Difference Metrics on OCT for Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis

Volpe G, Jurkute N, Girafa G, Zimmermann HG, Motamedi S, Bereuter C, Pandit L, D'Cunha A, Yeaman MR, Smith TJ, Cook LJ, Brandt AU, Paul[...]

Control strategies for emerging infectious diseases: Crimean-Congo hemorrhagic fever management

Srivastava S, Kumar S, Sharma PK, Rustagi S, Mohanty A, Donovan S, Henao-Martinez AF, Sah R, Franco-Paredes C. Control strategies for emerging infectious diseases: Crimean-Congo[...]

Single-cell detection of copy number changes reveals dynamic mechanisms of adaptation to antifungals in Candida albicans

Zhou X, Hilk A, Solis NV, Scott N, Beach A, Soisangwan N, Billings CL, Burrack LS, Filler SG, Selmecki A. Single-cell detection of copy number[...]